Engineered immune cells show promise against tough childhood cancers

This study tested a new treatment for children and young adults (ages 1–39) with leukemia or lymphoma that did not respond to standard therapy. The treatment involved taking a patient's own white blood cells, modifying them in a lab to target a protein called CD22 on cancer cells, and infusing them back. The goal was to see if this approach is safe and can shrink or eliminate the cancer. Participants received chemotherapy before the cell infusion and were monitored closely for side effects and response.